MODERNA INC

Moderna CFO James Mock buys 2,475 shares—showing insider confidence in Moderna’s mRNA strategy, biotech trends, and future growth potential.

Moderna insider grants signal confidence in mRNA‑1010 influenza vaccine, fueling a 19.8% share rise and 111% annual growth—investors see long‑term upside.

Insider buying at Moderna signals confidence: Horning, Rubenstein & Hussain purchase shares as the company drives 10% FY‑2026 revenue growth, cost control, and an expanding mRNA pipeline, boosting investor optimism.

Moderna insider buys signal confidence in its mRNA vaccine & therapeutic expansion, with strong pipeline prospects, global reach, and competitive edge.

Moderna’s legal chief buys shares after a $2.25B patent settlement, showing insider confidence and a clearer IP roadmap for investors.

Moderna CEO Stéphane Bancel buys 250,932 shares on March 1, 2026 – a sign of continued confidence in the mRNA company’s growth into oncology and cardiovascular therapeutics.

Moderna CFO’s 2026 share sale shows routine insider trading, but highlights the firm’s shift from COVID‑volume to value‑based mRNA therapeutics and how digital‑health, AI and reimbursement trends drive future growth.

Moderna CEO Stéphane Bancel’s recent 11,271‑share PSUs vest signals confidence in the company’s mRNA pipeline, while mitigating dilution and boosting investor confidence amid regulatory and revenue‑diversification challenges.